After raising AU$40 million (US$25.9 million) earlier this year to advance lead candidate VP-001 for treating retinitis pigmentosa type 11, PYC Therapeutics is now advancing PYC-003 to the clinic for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback